Table 2 Comparison of safety parameters after treatment with placebo or indacaterol in the whole study population.

From: Effects of β2-receptor stimulation by indacaterol in chronic heart failure treated with selective or non-selective β-blockers: a randomized trial

  

Placebo

Indacaterol

p

 

NYHA Class

1.9 ± 0.6

1.8 ± 0.5

0.2623

SBP (mmHg)

122 ± 16

128 ± 21

0.1901

DBP (mmHg)

76 ± 7

76 ± 10

0.7752

24-hours Holter Recording

Mean HR (bpm)

65 ± 9

66 ± 10

0.7098

Maximum HR (bpm)

95 ± 14

102 ± 24

0.0321

Minimum HR (bpm)

54 ± 6

54 ± 9

0.3843

VE (n/hour)

32.5 (11;128)

17.5 (5;85)

0.9721

SVE (n/hour)

1.4 (0;4)

1.4 (0;5)

0.5000

Couples (n)

3 (0;37)

4 (0;43)

0.9442

SV Run (n)

0 (0;0)

0 (0;0)

0.8811

V Run (n)

0 (0;1)

0 (0;1)

0.3224

Triplettes (n)

0 (0;0)

0 (0;1)

0.2927

Blood Sample

Glucose (mg/dl)

127 ± 43

124 ± 36

0.4560

Creatinine (mg/dl)

1.1 ± 0.3

1.12 ± 0.3

0.3725

BNP (pg/ml)

170 (50;423)

174 (60;358)

0.1578

Hb (g/dl)

13.9 ± 1.4

13.9 ± 1.5

0.1028

MLWHF Score

15 (7;28)

12 (4;27)

0.3079

  1. NYHA = NewYork Heart Association; SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; HR = Heart Rate; VE = Ventricular Ectopies; SVE = SupraVentricular Ectopies; SV = SupraVentricular; V = Ventricular; BNP = Brain Natriuretic Peptide; Hb = Haemoglobin; MLWHF = Minnesota Living With Heart Failure.
Back to article page